Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin

被引：0
|
作者：
Cheryl A Sherman-Baust
Kevin G Becker
William H Wood III
Yongqing Zhang
Patrice J Morin
机构：
[1] National Institute on Aging,Laboratory of Molecular Biology and Immunology
[2] National Institute on Aging,Research Resource Branch
[3] Johns Hopkins Medical Institutions,Department of Pathology
来源：
Journal of Ovarian Research | / 4卷
关键词：
Ovarian Cancer; Paclitaxel; Doxorubicin; Drug Resistance; Ovarian Cancer Cell;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Intraperitoneal cisplatin and paclitaxel in ovarian cancer
    Armstrong, DK
    Bundy, B
    Wenzel, L
    Huang, HQ
    Baergen, R
    Lele, S
    Copeland, LJ
    Walker, JL
    Burger, RA
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01): : 34 - 43
  • [22] Intraperitoneal cisplatin and paclitaxel in ovarian cancer
    Hariprasad, Roopa
    Kumar, Lalit
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2006, 27 (03) : 35 - 38
  • [23] Overcoming chemotherapy resistance of ovarian cancer cells by liposomal cisplatin: Molecular mechanisms unveiled by gene expression profiling
    Koch, Martin
    Krieger, Michaela L.
    Stoelting, Daniel
    Brenner, Norbert
    Beier, Manfred
    Jaehde, Ulrich
    Wiese, Michael
    Royer, Hans-Dieter
    Bendas, Gerd
    BIOCHEMICAL PHARMACOLOGY, 2013, 85 (08) : 1077 - 1090
  • [24] Esomeprazole Alleviates Cisplatin Resistance by Inhibiting the AKT/mTOR Pathway in Ovarian Cancer Cells
    Duan, Jingya
    Zhang, Zisen
    Du, Jinfeng
    Zhang, Jihua
    Li, Minmin
    Li, Canyu
    ONCOTARGETS AND THERAPY, 2023, 16 : 425 - 440
  • [25] Role of clusterin in paclitaxel resistance in ovarian cancer cells
    Hassan, Mohamed K.
    Watari, Hidemichi
    Sakuragi, Noriaki
    CANCER RESEARCH, 2006, 66 (08)
  • [26] Low miR-522 expression is correlated with paclitaxel resistance in ovarian cancer cells
    Miyamoto, Mayuko
    Sawada, Kenjiro
    Yoshimura, Akihiko
    Nakatsuka, Erika
    Kodama, Michiko
    Hashimoto, Kae
    Mabuchi, Seiji
    Kimura, Tadashi
    CANCER RESEARCH, 2018, 78 (13)
  • [27] Low miR-522 expression is related to paclitaxel resistance in ovarian cancer cells
    Miyamoto, Mayuko
    Sawada, Kenjiro
    Nakamura, Koji
    Kobayashi, Masaki
    Mabuchi, Seiji
    Kimura, Tadashi
    CANCER SCIENCE, 2018, 109 : 392 - 392
  • [28] A phase I study of paclitaxel, doxorubicin, and cisplatin in patients with previously untreated epithelial ovarian cancer
    Naumann, RW
    Alvarez, RD
    Omura, GA
    Segars, E
    Kilgore, LC
    Partridge, EE
    GYNECOLOGIC ONCOLOGY, 1998, 71 (03) : 450 - 453
  • [29] Cisplatin, paclitaxel and escalating doses of doxorubicin (TAP) in advanced ovarian cancer: a phase I trial
    Onda, T
    Katsumata, N
    Tsunematsu, R
    Yasugi, T
    Mushika, M
    Yamamoto, K
    Fujii, T
    Hirakawa, T
    Kamura, T
    Saito, T
    Yoshikawa, H
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2004, 34 (09) : 540 - 546
  • [30] The synergistic mechanisms of propofol with cisplatin or doxorubicin in human ovarian cancer cells
    Sue, Sung-How
    Tseng, Wei-Cheng
    Wu, Zih-Syuan
    Huang, Shih-Ming
    Chen, Jia-Lin
    Wu, Zhi-Fu
    Lai, Hou-Chuan
    JOURNAL OF OVARIAN RESEARCH, 2024, 17 (01)
12345